A New Market for ADHD Treatment?
|
TOOLBOX
   Resize
COMMENT
 Discussion Policy
 CLOSE
Comments that include profanity or personal attacks or other inappropriate comments or material will be removed from the site. Additionally, entries that are unsigned or contain "signatures" by someone other than the actual author will be removed. Finally, we will take steps to block users who violate any of our posting standards, terms of use or privacy policies or any other policies governing this site. Please review the full rules governing commentaries and discussions. You are fully responsible for the content that you post.
Who's Blogging  |
Tuesday, May 27, 2008; 3:10 PM
Seems as though everyone was reporting yesterday on a new study published online in Occupational and Environmental Medicine (one of the British Medical Journals). The study found that among 7,075 adult workers ages 18 to 44 from 10 countries, folks who reported symptoms of attention-deficit/hyperactivity disorder (ADHD) worked an average of 22.1 days less in a year than those without ADHD. That's a whole month of missed work. But none of the accounts I read mentioned that the study was funded by, in addition to the usual government agencies in the U.S. and other countries, a whole raft of pharmaceutical companies, including the makers of some ADHD drugs. In other words, companies that would stand to benefit if more potential users of their medications could be identified. It was my sharp-eyed editor who pointed the funders out to me. For the record, here's what the study found: Most of the
